title: G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial.
abstract: We have undertaken a prospective randomized study in 90 patients with relapsed or resistant lymphomas to assess the value of G-CSF (lenograstim) in the acceleration of myeloid recovery after peripheral blood stem cell transplantation (PBSCT). A common regimen of cyclophosphamide 1.5 g/m2 on day 1 and lenograstim 263 microg s.c. on days 2-10 with two aphereses on days 10 and 11 was used for stem cell mobilization. 77% of patients achieved an adequate PBSC collection in two harvests (> 2 x 10(8) MNC/kg or > 2 x 10(6) CD34+ cells/kg). 65 patients went on to receive high-dose BEAM chemotherapy and engraftment data was available for 62. 34 patients had been randomized to receive lenograstim 263 microg/d s.c. and 28 to no growth factor. The median time to ANC > 0.5 x 10(9)/l was 9 d in the lenograstim arm versus 12.5 d in the no-lenograstim arm (P=0.0001). This was associated with a median duration of time in hospital post PBSCT of 13 d in the lenograstim arm versus 15.5 d in the no-lenograstim arm (P=0.0002). Median days to platelet independence, platelet transfusions, incidence of infection and red cell transfusion were the same in both arms. These data indicate that lenograstim significantly accelerated myeloid recovery after PBSCT and shortened the duration of hospital stay.
authors.affiliation: University College London Hospitals.
authors.forename: D C
authors.initials: DC
authors.lastname: Linch
authors.forename: D W
authors.initials: DW
authors.lastname: Milligan
authors.forename: D A
authors.initials: DA
authors.lastname: Winfield
authors.forename: S M
authors.initials: SM
authors.lastname: Kelsey
authors.forename: S A
authors.initials: SA
authors.lastname: Johnson
authors.forename: T J
authors.initials: TJ
authors.lastname: Littlewood
authors.forename: G M
authors.initials: GM
authors.lastname: Smith
authors.forename: R M
authors.initials: RM
authors.lastname: Hutchinson
authors.forename: A H
authors.initials: AH
authors.lastname: Goldstone
authors.forename: A K
authors.initials: AK
authors.lastname: Fielding
authors.forename: G
authors.initials: G
authors.lastname: Vaughan Hudson
mesh_terms: D000328:Adult; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007958:Leukocyte Count; D008223:Lymphoma / Q000628:therapy*; D008875:Middle Aged; D009503:Neutropenia / Q000628:therapy*; D009504:Neutrophils / Q000473:pathology; D013997:Time Factors
chemical_list: D016179:Granulocyte Colony-Stimulating Factor